Literature DB >> 28403629

Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.

Tao He1,2, Meiying Zhang1,3, Ruipan Zheng1,3, Shufang Zheng2, Enqiang Linghu1, James G Herman3, Mingzhou Guo1.   

Abstract

AIM: The expression of human SLFN11 was reported to sensitize cancer cells to DNA damaging agents. This study is to explore the epigenetic change and the function of SLFN11 in human colorectal cancer (CRC). MATERIALS &
METHODS: Six CRC cell lines and 128 primary CRC samples were used.
RESULTS: SLFN11 was methylated in 55.47% (71/128) of primary CRC. The expression of SLFN11 was regulated by promoter region methylation. Methylation of SLFN11 was significantly associated with age, poor 5-year overall survival and 5-year relapse-free survival (all p < 0.05). SLFN11 suppressed CRC cell growth both in vitro and in vivo and sensitized CRC cells to cisplatin.
CONCLUSION: SLFN11 is frequently methylated in human CRC, and the expression of SLFN11 is regulated by promoter region methylation. Methylation of SLFN11 reduced the sensitivity of CRC cells to cisplatin.

Entities:  

Keywords:  DNA damage repair; SLFN11; cisplatin; colorectal cancer; epigenetics; methylation

Mesh:

Substances:

Year:  2017        PMID: 28403629     DOI: 10.2217/epi-2017-0019

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  25 in total

1.  Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.

Authors:  Edoardo Isnaldi; Domenico Ferraioli; Lorenzo Ferrando; Alberto Ballestrero; Gabriele Zoppoli; Sylvain Brohée; Fabio Ferrando; Piero Fregatti; Davide Bedognetti
Journal:  Breast Cancer Res Treat       Date:  2019-06-20       Impact factor: 4.872

Review 2.  Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Authors:  Junko Murai; Anish Thomas; Markku Miettinen; Yves Pommier
Journal:  Pharmacol Ther       Date:  2019-05-23       Impact factor: 12.310

3.  The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Authors:  Laetitia Marzi; Ludmila Szabova; Melanie Gordon; Zoe Weaver Ohler; Shyam K Sharan; Michael L Beshiri; Moudjib Etemadi; Junko Murai; Kathleen Kelly; Yves Pommier
Journal:  Clin Cancer Res       Date:  2019-08-13       Impact factor: 12.531

4.  PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.

Authors:  Ran An; Jueyu Liu; Jing He; Fei Wang; Qing Zhang; Qiang Yu
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 5.  Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review.

Authors:  Farzaneh Ghadiri Moghaddam; Safar Farajnia; Mohammad Karbalaei-Mahdi; Laleh Monir
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.742

Review 6.  DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?

Authors:  Nuno Tiago Tavares; Saulė Gumauskaitė; João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

Review 7.  Small-cell lung cancer: what we know, what we need to know and the path forward.

Authors:  Adi F Gazdar; Paul A Bunn; John D Minna
Journal:  Nat Rev Cancer       Date:  2017-10-27       Impact factor: 60.716

8.  Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer.

Authors:  Wushuang Du; Aiai Gao; James G Herman; Lidong Wang; Lirong Zhang; Shunchang Jiao; Mingzhou Guo
Journal:  Cancer Sci       Date:  2021-05-16       Impact factor: 6.716

9.  Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.

Authors:  Tsuyoshi Takashima; Naoya Sakamoto; Junko Murai; Daiki Taniyama; Ririno Honma; Shoichi Ukai; Ryota Maruyama; Kazuya Kuraoka; Vinodh N Rajapakse; Yves Pommier; Wataru Yasui
Journal:  Virchows Arch       Date:  2020-05-30       Impact factor: 4.535

Review 10.  A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.

Authors:  Bingnan Zhang; Kavya Ramkumar; Robert John Cardnell; Carl Michael Gay; C Allison Stewart; Wei-Lien Wang; Junya Fujimoto; Ignacio I Wistuba; Lauren Averett Byers
Journal:  Br J Cancer       Date:  2021-07-22       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.